DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Research summary · not a treatment plan
TB-500
TB-500 Accelerated Wound Healing
- US pathway
- Awaiting FDA
- Studied for
- recovery
- Route
- subcutaneous
01
Dosing as studied
2.0–2.5 mg SQ, 2x/week loading; 2.0 mg every 2 weeks maintenance.
02
Cycle length
4–8 weeks loading, then maintenance
03
Contraindications
Active cancer or history of malignancy.
04
Notes
Thymosin Beta-4 fragment; often stacked with BPC-157.
05
Regulatory status
The Peptide Association does not endorse or recommend any specific treatment protocol. This page summarizes how TB-500 has been used and studied. Whether it is right for you, and at what dose, is a decision for a licensed clinician.
TB-500 is not FDA-approved, and as of October 2026 FDA has not finalized whether pharmacies may compound it.
This protocol is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide therapy.